NEVVI Medicare utilization intelligence

← back

HAMAD, AMARMD NPI 1598765166 Clinician

Medical Oncology · OAK LAWN, IL

Specialty Medical Oncology — from billed Medicare claims
In practice about 41 years since medical school (class of 1985, self-reported to CMS)
Location OAK LAWN, IL · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 52 codes billed · 128,341 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
AFFILIATED ONCOLOGISTS LLC
2019–2026
BONAVENTURE MEDICAL FOUNDATION LLC
2024

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2007-07

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J1439 Injection, ferric carboxymaltose, 1 mg
J9299 Injection, nivolumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9267 Injection, paclitaxel, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J9312 Injection, rituximab, 10 mg
J1437 Injection, ferric derisomaltose, 10 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J2469 Injection, palonosetron hcl, 25 mcg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J9190 Injection, fluorouracil, 500 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J3475 Injection, magnesium sulfate, per 500 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
96375 Injection of additional new drug or substance into vein
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
71260 Ct scan of chest with contrast
96360 Infusion into a vein for hydration, 31-60 minutes
J3490 Unclassified drugs
96411 Administration of additional new drug or substance into vein using push technique
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J7030 Infusion, normal saline solution , 1000 cc
74177 Ct scan of abdomen and pelvis with contrast
36591 Collection of blood sample from implanted device
70491 Ct scan of soft tissue of neck with contrast
71250 Ct scan of chest without contrast
96374 Injection of drug or substance into vein
96523 Irrigation of implanted venous access drug delivery device
36415 Insertion of needle into vein for collection of blood sample
38222 Biopsy and aspiration of bone marrow sample for diagnosis

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.